Abstract
Mood disorders rank among the leading causes of disability worldwide, and are characterized by biological, emotional, psychological and cognitive symptoms. The monoamine hypothesis of depression fails to provide a comprehensive theory to account for this complex symptomatology, or the therapeutic action of drugs currently available for the treatment of mood disorders. Alternative theories have focused on the function of the hypothalamic–pituitary–adrenal (HPA) axis, and particularly on the deleterious effects of hypercortisolemia on mood, cognition and neuronal architecture. This article reviews the evidence suggesting that HPA axis dysfunction and maladaptive responses to stress may have a central role in the pathophysiology of mood disorders. Recent novel therapeutic strategies that target the HPA axis are also discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
